The offering consists of 10,003,889 shares of common stock alongside 1,111,111 pre-funded warrants priced at $8.9999 each. Underwriters have also been granted a 30-day option to purchase an additional 1,667,250 shares, which could further increase the total proceeds. Morgan Stanley, J.P. Morgan, Leerink Partners, and Mizuho are managing the sale, which was initiated under a shelf registration statement filed with the SEC last year.

REGENXBIO intends to utilize the capital to support its ongoing development of gene therapies, including its late-stage pipeline for Duchenne muscular dystrophy and retinal diseases. The company currently collaborates with AbbVie and Nippon Shinyaku on several programs utilizing its proprietary AAV platform.